Previous Close | 4.7000 |
Open | 4.7000 |
Bid | 6.0000 |
Ask | 8.3000 |
Strike | 15.00 |
Expire Date | 2024-08-16 |
Day's Range | 4.7000 - 4.7000 |
Contract Range | N/A |
Volume | |
Open Interest | 79 |
BOSTON, May 30, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City.
BOSTON, May 21, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 2024. B
It's been a sad week for Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ), who've watched their investment drop 14% to...